Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor

Journal of Psychopharmacology

Volumn 21, Issue 8, 2007, Pages 820-825

  Angelucci, Francesco ^a,b,c   Ricci, Valerio ^a   Pomponi, Massimiliano ^a   Conte, Gianluigi ^a   Mathé, Aleksander A ^c   Attilio Tonali, Pietro ^a,b   Bria, Pietro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BDNF; Cocaine; Heroin; Human; NGF

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; COCAINE; DIAMORPHINE; NERVE GROWTH FACTOR; NEUROTROPHIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; RISK; SCHIZOPHRENIA;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; COCAINE-RELATED DISORDERS; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; NERVE GROWTH FACTOR; PSYCHOTIC DISORDERS;

EID: 35648931553     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107078491     Document Type: Article

References (50)

1. Angelucci F., Mathe A.A., Aloe L. (2004) Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res 146: 151 - 165
2. Bolla K.I., Funderburk F.R., Cadet J.L. (2000) Differential effects of cocaine and cocaine alcohol on neurocognitive performance. Neurology 54: 2285 - 2292
3. Browne S.E., Lin L., Mattsson A., Georgievska B., Isacson O. (2001) Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. Exp Neurol 170: 36 - 47
4. Cantor-Graae E., Nordstrom L.G., McNeil T.F. (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48: 69 - 82
5. Canudas A.M., Pezzi S., Canals J.M., Pallas M., Alberch J. (2005) Endogenous brain-derived neurotrophic factor protects dopaminergic nigral neurons against transneuronal degeneration induced by striatal excitotoxic injury. Brain Res Mol Brain Res 134: 147 - 154
6. Cheng C.Y., Hong C.J., Yu Y.W., Chen T.J., Wu H.C., Tsai S.J. (2005) Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res 140: 86 - 90
7. Cipolli C., Galliani I. (1987) Addiction time and intellectual impairment in heroin users. Psychol Rep 60: 1099 - 1105
8. Connor B., Dragunow M. (1998) The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev 27: 1 - 39
9. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., Santin A., Kapczinski F. (2006) Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 398: 215 - 219
10. Dalley J.W., Laane K., Pena Y., Theobald D.E., Everitt B.J., Robbins T.W. (2005) Attentional and motivational deficits in rats withdrawn from intravenous self-administration of cocaine or heroin. Psychopharmacology (Berl) 182: 579 - 587
11. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. (2003) The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257 - 269
12. Ettenberg A., MacConell L.A., Geist T.D. (1996) Effects of haloperidol in a response-reinstatement model of heroin relapse. Psychopharmacology 124: 205 - 210
13. Filip M., Faron-Gorecka A., Kusmider M., Golda A., Frankowska M., Dziedzicka-Wasylewska M. (2006) Alterations in BDNF and trkB mRNAs following acute or sensitizing cocaine treatments and withdrawal. Brain Res 1071: 218 - 225
14. Gervasoni N., Aubry J.M., Bondolfi G., Osiek C., Schwald M., Bertschy G., Karege F. (2005) Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51: 234 - 238
15. Grimm J.W., Lu L., Hayashi T., Hope B.T., Su T.P., Shaham Y. (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 23: 742 - 747
16. Guerra D., Sole A., Cami J., Tobena A. (1987) Neuropsychological performance in opiate addicts after rapid detoxification. Drug Alcohol Depend 20: 261 - 270
17. Ha D.H., Robertson R.T., Roshanaei M., Weiss J.H. (1999) Enhanced survival and morphological features of basal forebrain cholinergic neurons in vitro: role of neurotrophins and other potential cortically derived cholinergic trophic factors. J Comp Neurol 406: 156 - 170
18. Hester R., Garavan H. (2004) Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci 24: 11017 - 11022
19. Huang T.L., Lee C.T. (2006) Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res 40: 664 - 668
20. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230 - 232
21. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. (2002 a) Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatr Res 109: 143 - 148
22. Karege F., Schwald M., Cisse M. (2002 b) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328: 261 - 264
23. Kastin A.J., Pan W., Maness L.M., Banks W.A. (1999) Peptides crossing the blood-brain barrier: some unusual observations. Brain Res 848: 96 - 100
24. Kim D.J., Roh S., Kim Y., Yoon S.J., Lee H.K., Han C.S., Kim Y.K. (2005) High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci Lett 388: 112 - 115
25. Klongpanichapak S., Govitrapong P., Sharma S.K., Ebadi M. (2006) Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10. Neurochem Res 31: 303 - 311
26. Lad S.P., Neet K.E., Mufson E.J. (2003) Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2: 315 - 334
27. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Schott K., Langer H., Gawaz M. (2006) Decreased brain-derived neurotrophic factor (BDNF). and betathromboglobulin (beta-TG)-blood levels in Alzheimer's disease. Thromb Haemost 96: 102 - 103
28. Le Foll B., Diaz J., Sokoloff P. (2005) A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. Neuroreport 16: 175 - 178
29. Lundqvist T. (2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 81: 319 - 330
30. Maren S., Fanselow M.S. (1995) Synaptic plasticity in the basolateral amygdala induced by hippocampal formation stimulation in vivo. J Neurosci 15: 7548 - 7564
31. Meredith G.E., Callen S., Scheuer D.A. (2002) Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 949: 218 - 227
32. Meshul C.K., Noguchi K., Emre N., Ellison G. (1998) Cocaine-induced changes in glutamate and GABA immunolabeling within rat habenula and nucleus accumbens. Synapse 2: 211 - 220
33. Norman A.B., Norman M.K., Hall J.F., Tsibulsky V.L. (1999) Priming threshold: a novel quantitative measure of the reinstatement of cocaine self-administration. Brain Res 831: 165 - 174
34. Olsen G.D. (1995) Potential mechanisms of cocaine-induced developmental neurotoxicity: a minireview. Neurotoxicology 16: 159 - 167
35. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. (1998) Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37: 1553 - 1561
36. Parikh V., Evans D.R., Khan M.M., Mahadik S.P. (2003) Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 60: 117 - 123
37. Pierce R., Bari A. (2001) The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci 12: 95 - 110
38. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511 - 2518
39. Schlaepfer T., Lancaster E., Heidbreder R., Strain E., Kosel M., Fisch H., Pearlson G. (2006) Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol 2: 147 - 153
40. Shaham Y., Stewart J. (1996) Effects of opioid and dopamine receptor antagonists on relapse induced by stress and reexposure to heroin in rats. Psychopharmacology 125: 385 - 391
41. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. (2003) Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 351: 111 - 114
42. Spain J.W., Newsom G.C. (1991) Chronic opioids impair acquisition of both radial maze and Y-maze choice escape. Psychopharmacology (Berl) 105: 101 - 106
43. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Zhang X.Y. (2005) Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382: 27 - 32
44. Thirthalli J., Benegal V. (2006) Psychosis among substance users. Curr Opin Psychiatr 19: 239 - 245
45. Thoenen H. (1995) Neurotrophins and neuronal plasticity. Science 270: 593 - 598
46. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. (2002) Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatr Res 110: 249 - 257
47. van den Brink W., van Ree J. (2003) Pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 13: 476 - 487
48. Wise R. (1996) Neurobiology of addiction. Curr Opin Neurobiol 6: 243 - 251
49. Yasutake C., Kuroda K., Yanagawa T., Okamura T., Yoneda H. (2006) Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: Comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 256: 402 - 406
50. Zanardini R., Gazzoli A., Ventriglia M., Perez J., Bignotti S., Rossini P.M., Gennarelli M., Bocchio-Chiavetto L. (2006) Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 91: 83 - 86